Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Pulmovinci in Idiopathic Pulmonary Fibrosis: NCT06081621 Clinical Landscape Report 2026
15 October 2026
NCT06081621 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
RZ-001 in Glioblastoma Multiforme: NCT06102525 Clinical Landscape Report 2026
15 October 2026
NCT06102525 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Glioblastoma Multiforme: NCT06072586 Clinical Landscape Report 2026
15 October 2026
NCT06072586 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Glioblastoma Multiforme: NCT06095375 Clinical Landscape Report 2026
15 October 2026
NCT06095375 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Recurrent Glioblastoma: NCT06097975 Clinical Landscape Report 2026
15 October 2026
NCT06097975 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bexotegrast in Idiopathic Pulmonary Fibrosis: NCT06097260 Clinical Landscape Report 2026
15 October 2026
NCT06097260 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
AMT-162 in Amyotrophic Lateral Sclerosis: NCT06100276 Clinical Landscape Report 2026
15 October 2026
NCT06100276 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TDI-01 in Idiopathic Pulmonary Fibrosis: NCT06102083 Clinical Landscape Report 2026
15 October 2026
NCT06102083 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Vebreltinib in Glioblastoma: NCT06105619 Clinical Landscape Report 2026
15 October 2026
NCT06105619 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Rosuvastatin Calcium in Metabolic Dysfunction Associated Steatohepatitis: NCT06105060 Clinical Landscape Report 2026
15 October 2026
NCT06105060 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Gatuzosiran in Metabolic Dysfunction Associated Steatohepatitis: NCT06104319 Clinical Landscape Report 2026
15 October 2026
NCT06104319 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Dapagliflozin in Diabetes Mellitus, Type 2: NCT06117137 Clinical Landscape Report 2026
15 October 2026
NCT06117137 clinical landscape for Diabetes Mellitus, Type 2: endpoints, sponsor, phase, geography, readouts, asset context and development white space.